Related by context. All words. (Click for frequent words.) 68 OXi# 68 ENMD # 67 selective kinase inhibitor 66 PXD# 66 Perifosine 66 HGS ETR1 66 histone deacetylase HDAC inhibitor 65 PEG SN# 65 ganetespib 64 antitumor activity 64 Symadex 64 alvespimycin 64 kinase inhibitor 64 AEZS 64 Carfilzomib 64 CYC# 64 obatoclax 64 GRN#L 63 Aurora kinase 63 imetelstat 63 CTCE 63 Sapacitabine 63 Azedra 63 vascular disrupting agent 63 INCB# [001] 63 axitinib 63 CR# vcMMAE 63 MGCD# [001] 63 AEG# 62 HGS ETR2 62 targeting CD# 62 HGS# 62 protein kinase inhibitor 62 JAK inhibitor 62 ARRY 62 eniluracil 62 investigational humanized monoclonal antibody 62 CCR9 antagonist 62 NKTR 62 atacicept 62 Omacetaxine 62 lintuzumab 62 AP# [003] 62 PRT# 62 sapacitabine 62 RGB # 62 HDAC inhibitor 62 PLK1 SNALP 62 Debio 62 XL# [003] 61 Voreloxin 61 ARRY # 61 proteasome inhibitor 61 depsipeptide 61 glufosfamide 61 seliciclib 61 anti leukemic 61 MEK inhibitors 61 BAY #-# 61 humanized anti 61 CA4P 61 angiogenesis inhibitor 61 Blinatumomab 61 HER2 positive metastatic breast 61 PSMA ADC 61 Phase #b/#a clinical 61 multi kinase inhibitor 61 hematological malignancies 61 JAK1 61 GRN# 61 enzastaurin 61 Atiprimod 61 hematological cancers 61 HSP# inhibitor 61 CUDC 61 MEK inhibitor 61 ON #.Na 61 GSK # 61 forodesine 61 Traficet EN 61 #ME# 61 perifosine 61 phase IIb clinical 61 HCV protease 61 orally bioavailable 61 relapsed refractory multiple myeloma 61 Tyrima 61 relapsed multiple myeloma 61 registrational trial 61 seliciclib CYC# 61 Angiolix 60 CCX# 60 MLN# 60 PRTX 60 IMC A# 60 Bezielle 60 FOLOTYN ® 60 Hsp# inhibition 60 LymphoStat B 60 CD# monoclonal antibody 60 xenograft models 60 pan HDAC inhibitor 60 PDE4 inhibitor 60 ELACYT 60 Sym# 60 Annamycin 60 Panzem R NCD 60 Factor VIIa 60 oral prodrug 60 HCD# [002] 60 CYT# 60 tubulin inhibitor 60 HCV protease inhibitor 60 BiTE antibody 60 cutaneous T cell 60 AQ4N 60 signal transduction inhibitor 60 PCK# 60 NXL# 60 GMX# 60 anticancer agent 60 AEGR 60 EZN 60 novel histone deacetylase 60 mitogen activated ERK kinase 60 BAL# [001] 60 drug conjugate 60 delta isoform 60 Archexin 60 cetuximab Erbitux R 60 OncoVEX GM CSF 60 PNP inhibitor 60 HuLuc# 60 INGN 60 immunotherapeutic 60 Aplidin 60 PS# [001] 60 FGFR 60 Panzem 60 R#/MEM # 59 voreloxin 59 Phase Ib II 59 IMGN# 59 mertansine 59 Tarvacin TM 59 vascular disrupting agents 59 Quinamed 59 immunomodulating 59 Panzem R 59 OMP #M# 59 PKC# 59 APOPTONE 59 Hsp# Inhibitor 59 solid tumors 59 huC# DM4 59 Phase Ib 59 LY# [003] 59 metaglidasen 59 belinostat 59 radiation sensitizer 59 XmAb# 59 cell lymphoma CTCL 59 humanized monoclonal antibody 59 CBLC# 59 favorable pharmacokinetic profile 59 JAK2 inhibitor 59 CYT# potent vascular disrupting 59 IMMU 59 Xanafide 59 JAK inhibitors 59 Azixa 59 RDEA# 59 vidofludimus 59 elesclomol 59 alpha folate receptor 59 ONX 59 Phase 1b 59 pertuzumab 59 Entremed 59 selective inhibitor 59 Bortezomib 59 velafermin belinostat 59 liposomal formulation 59 ISIS # 59 phase IIa clinical 59 evaluating tivozanib 58 IAP inhibitors 58 MT# MEDI 58 pomalidomide 58 TELINTRA 58 IAP inhibitor 58 Elesclomol 58 Amrubicin 58 preclinically 58 elotuzumab 58 Phase Ib clinical 58 proteasome inhibitors 58 AVN# [001] 58 carfilzomib 58 docetaxel Taxotere R 58 XL# XL# 58 imatinib Gleevec ® 58 Hsp# inhibitor 58 MEK inhibitor RDEA# 58 receptor tyrosine kinase inhibitor 58 zanolimumab 58 IMA# 58 vinca alkaloid 58 antibody MT# 58 GAP #B# 58 PSN# [002] 58 MDV# 58 VEGFR2 58 Alocrest 58 huN# DM1 58 cytotoxic 58 YONDELIS 58 Apaziquone 58 Cyclooxygenase Inhibiting Nitric Oxide 58 orally administered inhibitor 58 HQK 58 Alpharadin 58 RG# [001] 58 BCX# 58 Hsp# inhibitors 58 Cloretazine 58 CD# antibody [001] 58 tyrosine kinase inhibitor 58 sodium glucose cotransporter 58 Romidepsin 58 EGFr 58 IMC #B 58 HDAC Inhibitor 58 Seliciclib 58 Talabostat 58 Shigamabs ® 58 ProLindac 58 perifosine KRX 58 anticancer compound 58 TG# [003] 58 velafermin 58 Vidofludimus 58 CCR2 58 Guanilib 58 erlotinib Tarceva ® 58 EndoTAG TM -1 58 HuMax CD4 58 leukemia CLL 58 entinostat 58 immunomodulatory 58 oritavancin 58 CEQ# 58 kinase inhibitors 58 EGFR HER2 58 HuMax EGFr 58 Trastuzumab 58 MGd 58 Vicinium TM 57 TOCOSOL Paclitaxel 57 histone deacetylase inhibitor 57 AKT inhibitor 57 novel peptide 57 ixabepilone 57 Curaxin 57 oral proteasome inhibitor 57 otelixizumab 57 sunitinib malate 57 bafetinib 57 talabostat 57 Virulizin R 57 MOZOBIL 57 CD4 monoclonal antibody 57 Apoptone 57 mGluR2 NAM 57 triphendiol 57 epothilone 57 tesmilifene 57 Phase Ib clinical trials 57 mapatumumab 57 dasatinib Sprycel ® 57 antitumor 57 Advanced Renal Cell 57 telomerase inhibitor drug 57 IL #E 57 TREANDA 57 Ocrelizumab 57 Ceflatonin R 57 palifosfamide 57 investigational monoclonal antibody 57 heavily pretreated 57 registrational 57 immunomodulator 57 ONCONASE 57 CGEN # 57 BZL# 57 mTOR inhibitor 57 Phase Ib study 57 dacetuzumab 57 Exherin TM 57 tesetaxel 57 Virulizin ® 57 investigational compound 57 ADP receptor antagonist 57 omacetaxine 57 INT# [002] 57 non nucleoside inhibitor 57 Aplidin R 57 Exelixis XL# 57 polymerase inhibitor 57 CTAP# Capsules 57 tanespimycin 57 ApoB SNALP 57 Tamibarotene 57 TLR8 agonist 57 gemcitabine Gemzar ® 57 LHRH antagonists 57 LymphoStat B TM 57 anticancer agents 57 HspE7 57 PEG Interferon lambda 57 delafloxacin 57 picoplatin 57 reversible inhibitor 57 Brentuximab Vedotin SGN 57 Cloretazine ® 57 tezampanel 57 pralatrexate 57 adecatumumab 57 rNAPc2 57 ISTODAX 57 potent inhibitor 57 selective androgen receptor modulator 57 novel anticancer 57 preclinical efficacy 57 Onconase 57 selective inhibition 57 ALKS 57 Talactoferrin 57 reversible inhibitors 57 DXL# 57 anti amnesic 57 SAR# [004] 57 BIBW 57 oral ridaforolimus 57 Restanza 57 Opexa 57 ALN TTR 57 Sphingomab 57 polymerase inhibitors 57 BiTE 57 hypoxia activated prodrug 57 Solazed TM 57 molecularly targeted 57 trastuzumab DM1 T DM1 57 Trofex 57 CD3 monoclonal antibody 57 5 HT6 receptor 57 nicotinic alpha 7 56 farletuzumab 56 rALLy clinical trial 56 R roscovitine 56 antitumor effects 56 L Annamycin 56 EndoTAGTM 1 56 Aflibercept 56 bevacizumab Avastin ® 56 sunitinib Sutent ® 56 Myocet 56 romidepsin 56 Epothilones 56 ALN PCS 56 ponatinib 56 Intravenous CP 56 Bicifadine 56 metastatic colorectal 56 Phase 2b trial 56 Tarvacin 56 diabetic nephropathy 56 Preclinical studies 56 IgG1 antibody 56 ALN VSP 56 Pralatrexate 56 Daclizumab 56 panobinostat 56 pediatric acute lymphoblastic 56 OHR/AVR# 56 AZD# 56 mTOR inhibitors 56 Cyclacel Pharmaceuticals 56 Chemophase 56 tivozanib 56 Elagolix 56 Triolex 56 deforolimus 56 HuMax CD# 56 Troxatyl 56 highly selective inhibitor 56 proteasome inhibitor bortezomib 56 cutaneous T 56 bendamustine 56 alkylating agent 56 preclinical 56 ASA# 56 leukemia AML 56 ZYBRESTAT 56 CORT # 56 PDX pralatrexate 56 selective modulator 56 demonstrated antitumor activity 56 JAK3 56 agonistic human 56 MAXY G# 56 Phase 2a trial 56 SGLT2 56 ATL/TV# 56 Phase #/#a trial 56 Amigal 56 antibody MAb 56 mRCC 56 mouse xenograft models 56 synthetic retinoid 56 BRAF inhibitor 56 Hedgehog pathway 56 castrate resistant prostate cancer 56 Vilazodone 56 vivo efficacy 56 small molecule defensin 56 targeted radiotherapeutic 56 Intarcia 56 c MET 56 VEGF receptor 56 JAK2 56 pharmacokinetic PK 56 induce apoptosis 56 MEK Inhibitor 56 gefitinib Iressa 56 VEGF Trap 56 phase Ib 56 antiangiogenic 56 novel VDA molecule 56 Nanobody 56 IL# PE#QQR 56 small molecule 56 small molecule inhibitor 56 stable nucleic acid 56 cilengitide 56 partial agonist 56 Revlimid lenalidomide 56 Phase IIb clinical 56 Neulasta ® 56 ANAVEX #-# [003] 56 Squalamine 56 ATL# [001] 56 TTF Therapy 56 Ozarelix 56 cytotoxic chemotherapy 56 lupus nephritis 56 ErbB2 positive 56 ACHN 56 nucleoside analog 56 Stedivaze 56 pharmacodynamic PD 56 TKB# 56 Belinostat 56 PARP inhibitor 56 R#/MEM 56 Allovectin 7 56 elacytarabine 56 metastatic renal cell carcinoma 56 oncology therapeutics 56 ProSavin 56 Trofex TM 56 lymphoma CTCL 56 Dasatinib 56 VQD 56 EOquin TM 56 HDAC 56 isoform selective 56 IIa trial 56 KSP inhibitor 56 Clavis Pharma 56 EOquin 56 prostate cancer HRPC 56 cancer immunotherapies 56 CRLX# 56 Kinase Inhibitor 56 phase Ib clinical 56 Enzastaurin 56 advanced carcinoid 56 Targretin 56 hematologic malignancies 56 pharmacological chaperone 56 Serdaxin 56 ofatumumab 56 Nanobody ® 56 Harbor BioSciences 56 Zerenex 56 GLP toxicology studies 56 Irinotecan 56 leading oral taxane 56 novel topoisomerase 56 protein tyrosine phosphatase 1B 56 CIMZIA TM 56 VitiGam 56 anti angiogenic 56 AeroLEF TM 56 glucagon receptor 56 ongoing Phase 1b 55 HuMax HepC TM 55 systemic RNAi therapeutic 55 microtubule targeting 55 Tesetaxel 55 decitabine 55 refractory chronic lymphocytic 55 crizotinib PF # 55 resistant ovarian cancer 55 EpCAM 55 ANYARA 55 ITMN 55 CoFactor 55 oxidative stress inducer 55 hormone LHRH antagonist 55 Phase 2b clinical 55 MT#/MEDI-# 55 Proxinium TM 55 volociximab 55 Phase IIa trials 55 taxanes 55 XL# XL# XL# 55 Vandetanib 55 SERMs 55 Cloretazine R 55 Insegia 55 docetaxel chemotherapy 55 insulin sensitizer 55 highly selective adenosine 55 PRX # 55 androgen independent 55 Phase IIa clinical 55 epigenetic therapies 55 peripherally acting 55 adecatumumab MT# 55 Phase IIb trials 55 lintuzumab SGN 55 HRPC 55 DOS# 55 fosbretabulin 55 dasatinib Sprycel 55 TELCYTA 55 Curaxin CBLC# 55 clofarabine 55 preclinical compounds 55 histone methyltransferases HMTs 55 TRO# 55 eltrombopag 55 JAK2 inhibitors 55 XmAb ® 55 Æterna Zentaris 55 PI3K/mTOR 55 T DM1 55 NASDAQ ARRY 55 non nucleoside HCV 55 Phase 2a Clinical Trial 55 compound AEZS 55 palifosfamide Zymafos TM 55 Announces Poster Presentations 55 VEGFR2 inhibitor 55 DAVANAT 55 nucleoside tide 55 mGluR5 negative 55 CD# expressing 55 Bendavia 55 novel immunomodulatory 55 vaccine GRNVAC1 55 RNAi therapeutic 55 peptidic compound 55 sorafenib Nexavar ® 55 Fc fusion protein 55 Fibroblast Growth Factor Receptor 55 Nexavar ® 55 orally dosed 55 multikinase inhibitor 55 Cloretazine R VNP#M 55 OvaRex R 55 alpha antagonist 55 Phase 1b clinical trials 55 neratinib 55 LUX Lung 55 AEterna 55 immunotherapeutic agent 55 TRAIL receptor 55 kinase inhibition 55 anti fibrotic 55 Imprime PGG 55 Posiphen 55 immune modulating 55 Sudhir Agrawal D.Phil 55 candidate CRLX# 55 TAFA# 55 Zolinza 55 TKM ApoB 55 HDAC inhibitors 55 renin inhibitor 55 PI3K/Akt pathway inhibitor 55 Tumour Vascular Disrupting Agent 55 Peregrine Pharmaceuticals 55 IgG1 monoclonal antibody 55 potent antitumor activity 55 Celator 55 taxane 55 pralatrexate injection folate analogue 55 FOLOTYN 55 Deforolimus 55 TOPIGEN 55 chemotherapeutic drug 55 resolvin 55 OMP #R# 55 HER3 55 tafamidis 55 trastuzumab Herceptin 55 small molecule activator 55 small molecule tyrosine 55 cMET 55 myeloproliferative disorders 55 Phase 2a clinical 55 hematologic cancers 55 CD# CEA 55 Hedgehog Pathway Inhibitor 55 Tarceva TM 55 INCB# [002] 55 refractory multiple myeloma 55 SCH # 55 chemotherapeutics 55 essential thrombocythemia ET 55 vosaroxin 55 MAbs 55 MAGE A3 ASCI 55 Plicera 55 MAb 55 TORISEL 55 Denufosol 55 Phase 1b trial 55 neuroprotective properties 55 hormone refractory prostate cancer 55 TRV# [001] 55 PI3K inhibitor 55 2 methoxyestradiol 55 recurrent NSCLC 55 geldanamycin 55 platinum refractory 55 Inhalation Solution 55 VIDAZA 55 Beta catenin 55 tiapamil 55 darinaparsin ZIO 55 immunotherapeutics 55 AAG geldanamycin analog 55 Ceflatonin 55 potent anticancer 55 ARIKACE 55 ALTU 55 AACR NCI EORTC 55 DermaVir Patch 55 PI3K delta 55 SUTENT 55 ZACTIMA 55 Xcellerated T Cells 55 PI3K 55 nucleotide analog 54 ZEVALIN ® 54 PI3 kinase 54 Amplimexon 54 sodium thiosulfate STS 54 Cintredekin Besudotox 54 initiated Phase 1b 54 Cannabinor 54 PEP# [003] 54 refractory AML 54 Tezampanel 54 torezolid phosphate 54 pharmacodynamic 54 Protein Kinase C 54 PF # [001] 54 ulimorelin 54 cannabinor 54 investigational compounds 54 HCV polymerase inhibitors 54 cyclin dependent kinases CDKs 54 castration resistant prostate cancer 54 Marqibo 54 CDK cyclin dependent 54 Cutaneous T 54 Phase 2b Clinical Trial 54 chronic lymphocytic leukemia CLL 54 veltuzumab 54 Laquinimod 54 Golimumab 54 MNTX 54 IRX 2 54 PTP 1B 54 CLORETAZINE TM VNP#M 54 AKIP ™ 54 hypoxia inducible factor 54 NASDAQ PCYC 54 Gleevec resistant 54 induces apoptosis 54 PLX# 54 Metastatic Melanoma 54 Alzhemed TM 54 initiate Phase 1b 54 ridaforolimus 54 afatinib 54 cediranib 54 Protexia ® 54 preclinical studies 54 sorafenib Nexavar 54 goserelin 54 TriRima 54 compound PMX # 54 MORAb 54 Glufosfamide 54 darinaparsin 54 Allovectin 7 ® 54 chemotherapeutic 54 small molecule inhibitors 54 OncoVEX 54 teduglutide 54 MAXY alpha 54 TLR7 54 REP# 54 metastatic CRC 54 MOR# 54 EGFR inhibitors 54 gemcitabine cisplatin 54 Cethromycin 54 teriflunomide 54 NASDAQ ABII 54 Fleximer 54 Nasdaq RXII 54 virus HCV protease inhibitor 54 Taxotere ® 54 Lenocta 54 radezolid 54 Telcyta 54 antisense inhibitors 54 indibulin 54 myelofibrosis polycythemia vera 54 Homspera 54 L BLP# 54 Allovectin 7 R 54 IND enabling 54 GENR 54 panitumumab Vectibix 54 MYDICAR ® 54 Valortim 54 luteinizing hormone releasing 54 generation purine nucleoside 54 therapeutic monoclonal antibody 54 sunitinib 54 tyrosine kinase inhibitor TKI 54 PEG PAL 54 phase IIa 54 HGS ETR1 mapatumumab 54 Pharmion Corporation 54 brentuximab vedotin SGN 54 superficial bladder cancer 54 selective agonist 54 GSK# [001] 54 dextromethorphan quinidine 54 T#I mutant 54 azacitidine 54 dirucotide 54 metastatic hormone refractory 54 refractory Hodgkin lymphoma 54 Maribavir 54 Pazopanib 54 Chemokine Therapeutics 54 Tesmilifene 54 paclitaxel Taxol ® 54 Harry Palmin President 54 cabozantinib 54 cyclophilin inhibitor 54 DPP4 inhibitor 54 phase IIb 54 NP2 Enkephalin 54 Pemetrexed 54 Zevalin R Ibritumomab 54 milatuzumab 54 ADVEXIN 54 aflibercept 54 recurrent ovarian cancer 54 MGCD# [002] 54 Dapagliflozin 54 subcutaneous formulation 54 HDACi 54 A3 adenosine receptor 54 prostate cancer AIPC 54 antiproliferative effects 54 vorinostat 54 Defibrotide 54 telomerase therapeutic 54 rxRNA 54 Zybrestat 54 investigational oral 54 VAPRISOL 54 Vion Pharmaceuticals 54 Curaxins 54 NGX# 54 Litx 54 OMAPRO 54 inhaled formulation 54 XmAb ™ 54 BRIM2 54 maribavir 54 GVAX ® 54 Everolimus 54 visilizumab 54 assessing T DM1 54 BCR ABL 54 Viprinex 54 TACI Ig 54 dacetuzumab SGN 54 XL# XL# XL# XL# 54 Vidaza 54 gemcitabine 54 #/#/# Cytokinetics Incorporated 54 OvaRex ® MAb 54 HE# [002] 54 sorafenib tablets 54 chemotherapeutic agents 54 chronic myeloid leukemia CML 54 solithromycin 54 cyclin dependent kinase inhibitor 54 TKM PLK1 54 sPLA2 54 CCX# B 54 myelofibrosis 54 TPI ASM8 54 tumors GIST 54 renin inhibitors 54 bavituximab 54 KRN# 54 telomerase inhibitor 54 antisense 54 tranilast 54 Azedra TM 54 Tavocept 54 daclizumab 54 GSK '# 54 PHX# 54 immunosuppressive compound 54 refractory NSCLC 54 NU# [001] 53 Mipomersen 53 ZYBRESTAT fosbretabulin 53 relapsed SCLC 53 pancreatic colon 53 bortezomib Velcade R 53 anti mitotic 53 REOLYSIN ® 53 GAMMAGARD 53 c Raf kinase 53 Cisplatin 53 SCCHN 53 bortezomib Velcade ® 53 FLT3 53 Epratuzumab 53 celgosivir 53 imetelstat GRN#L 53 receptor partial agonist 53 XL# anticancer compounds 53 oral FTY# 53 imatinib Gleevec 53 phase IIb trial 53 TRC# 53 blinatumomab 53 Tanespimycin 53 Oncaspar 53 TMC# [002] 53 Clolar ® 53 EndoTAG TM 53 BiTE ® 53 Phase 2b study 53 immune modulators 53 XmAb 53 mda 7 53 metastatic renal cell 53 WT1 53 oncolytic virus therapies 53 Preclinical 53 Regado 53 ALN TTR# 53 drug GAP #B# 53 Rexahn Pharmaceuticals 53 phosphate S1P 53 refractory PTCL 53 RAV# 53 Marqibo TM 53 Fx #A 53 ASONEP 53 Survivin 53 human monoclonal antibody 53 investigational immunotherapy 53 humanized monoclonal 53 transthyretin TTR mediated amyloidosis 53 gamma secretase inhibitor 53 Immunotherapeutic 53 VELCADE melphalan 53 placebo controlled Phase 53 nab paclitaxel 53 PI3K Akt 53 Telintra 53 NEUMUNE 53 Velcade bortezomib 53 relapsed ovarian cancer 53 Lixivaptan 53 investigational pan BCR 53 Anticalin R 53 TRISENOX 53 Alfacell 53 Celgosivir 53 camptothecin 53 exon skipping 53 kidney urologic 53 sorafenib 53 Elotuzumab 53 selective antagonist 53 Phase 1a clinical 53 selectively inhibits 53 lomitapide 53 OTCBB PYTO 53 Onconova 53 leukemia ALL 53 MyVax R 53 Daniel Junius 53 Varespladib 53 XL# SAR# 53 Reolysin 53 Sunesis Pharmaceuticals 53 lymphoid malignancies 53 Valortim ® 53 Herceptin trastuzumab 53 Transave 53 trodusquemine 53 MAP# 53 tiuxetan 53 vaccines oncolytic virus 53 anti angiogenic agent 53 TRIOLEX 53 therapeutic antibody 53 Arqule 53 targeted kinase inhibitor 53 QuatRx 53 GED aPC 53 ALK inhibitor 53 talactoferrin 53 anti CD# antibodies 53 amrubicin 53 CB2 selective receptor agonist 53 antisense inhibitor 53 brivaracetam 53 BXT # 53 IMiDs 53 ovarian carcinoma 53 targeted antifolate 53 Combination REOLYSIN R 53 vilazodone 53 Pimavanserin 53 Phenoptin 53 BENLYSTA ® 53 investigational therapies 53 bosutinib 53 MET VEGFR2 53 teplizumab 53 AMEX INO 53 refractory indolent non 53 BCR ABL inhibitors 53 XMT 53 dependent kinase inhibitor 53 Phase 2a 53 relapsed MM 53 IMiDs R 53 Neuradiab 53 antitumoral 53 Triapine 53 ImmuneRegen BioSciences Inc. 53 Gemin X 53 ErbB3 53 bone metastasis 53 retapamulin 53 CBLB# 53 systemically administered 53 Lymphoseek ® 53 Shigamabs R 53 initiated Phase Ib 53 sphingosine 1 53 Catena ® 53 SNT MC# 53 Lu AA#